ArticleFrontiers in immunology2025
Fruquintinib saddles tumor immune tolerance by curbing pro-tumoral immature myeloid cell populations.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- VEGFC as a prognostic cytokine biomarker linking lymph node metastasis to immune suppression in breast cancer.European cytokine network · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Myeloid-derived cells, particularly immature populations and tumor-associated macrophages, play a pivotal role in establishing immune tolerance and suppressing antitumor responses, thereby promoting cancer progression. Macrophage-derived lymphatic endothelial cell progenitors (M-LECP) are a population of VEGFR3/FLT4/CD310 Results: Fruquintinib treatment significantly inhibited primary tumor growth, angiogenesis, and metastases in murine models of breast (4T1 and E0771) and colorectal (CT26 and MC38) cancer, respectively. Importantly, treatment with fruquintinib remodeled the tumor immune microenvironment of MC38 tumors by increasing the percentages of CD4 Conclusion: Overall, our findings offer new insights into the contribution of VEGFR3/FLT4/CD310 inhibition to restoring a pro-inflammatory tumor myeloid compartment and suggest M-LECP cells as candidate fruquintinib targets to overcome immunosuppression in tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.